ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma.
American journal of translational research（2023）
摘要
c-Met overexpression and activation is an essential mechanism of sorafenib resistance in HCC. Combination therapy of sorafenib plus c-Met inhibitor overcame the resistance of sorafenib-targeted therapy for HCC.
更多查看译文
关键词
ETS-1,Hepatocellular carcinoma,c-Met,sorafenib,sorafenib resistance
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要